• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sonnet Biotherapeutics Holdings Inc (NQ: SONN )

    0.7600 -0.0095 (-1.23%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 48,210
    Open 0.7700
    Bid (Size) 0.7407 (1)
    Ask (Size) 0.7659 (1)
    Prev. Close 0.7695
    Today's Range 0.7400 - 0.7775
    52wk Range 0.6239 - 6.600
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    SONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024
    SONN stock results show that Sonnet BioTherapeutics beat analyst estimates for earnings per share the third quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -56.82%
    -56.82%
    1 Month
    -11.26%
    -11.26%
    3 Month
    -53.09%
    -53.09%
    6 Month
    -58.81%
    -58.81%
    1 Year
    -88.43%
    -88.43%

    More News

    Read More
    Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Gold Rises 1%; Accenture Shares Surge After Q3 Results
    Via Benzinga
    Dow Edges Lower; US Current Account Deficit Widens In Q1
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Announces Review of Strategic Alternatives
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
    Via ACCESSWIRE
    SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
    Via ACCESSWIRE
    Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.